Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability

Chih Wen Chen; Tao Shen Ou; Wei Shone Chen; Jeng Kai Jiang; Shung Haur Yang; Huann Sheng Wang; Shih Ching Chang; Yuan Tzu Lan; Chun Chi Lin; Hung Hsin Lin; Sheng Chieh Huang; Hou Hsuan Cheng; Yi Wen Yang; Yu Zu Lin; Yee Chao; Ling Wei Wang; Hao Wei Teng

doi:10.1016/j.clcc.2023.03.003

Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability

Chih Wen Chen, Tao Shen Ou, Wei Shone Chen, Jeng Kai Jiang, Shung Haur Yang, Huann Sheng Wang, Shih Ching Chang, Yuan Tzu Lan, Chun Chi Lin, Hung Hsin Lin, Sheng Chieh Huang, Hou Hsuan Cheng, Yi Wen Yang, Yu Zu Lin, Yee Chao, Ling Wei Wang^*, Hao Wei Teng^*

^*此作品的通信作者

醫學系外科學科

研究成果: Article › 同行評審

1 引文斯高帕斯（Scopus）

摘要

Background: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM. Methods: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal. Results: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis. Conclusions: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.

原文	English
期刊	Clinical Colorectal Cancer
DOIs	https://doi.org/10.1016/j.clcc.2023.03.003
出版狀態	Accepted/In press - 2023

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.1016/j.clcc.2023.03.003

其它文件與鏈接

Link to publication in Scopus

引用此

Chen, C. W., Ou, T. S., Chen, W. S., Jiang, J. K., Yang, S. H., Wang, H. S., Chang, S. C., Lan, Y. T., Lin, C. C., Lin, H. H., Huang, S. C., Cheng, H. H., Yang, Y. W., Lin, Y. Z., Chao, Y., Wang, L. W., & Teng, H. W. (認可的出版社/出版中). Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2023.03.003

@article{c82c73e028fe405499104dcf1d327887,

title = "Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability",

abstract = "Background: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM. Methods: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal. Results: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis. Conclusions: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.",

keywords = "Anti-angiogenesis therapy, Colorectal cancer, Gene Ontology, Overall Survival",

author = "Chen, {Chih Wen} and Ou, {Tao Shen} and Chen, {Wei Shone} and Jiang, {Jeng Kai} and Yang, {Shung Haur} and Wang, {Huann Sheng} and Chang, {Shih Ching} and Lan, {Yuan Tzu} and Lin, {Chun Chi} and Lin, {Hung Hsin} and Huang, {Sheng Chieh} and Cheng, {Hou Hsuan} and Yang, {Yi Wen} and Lin, {Yu Zu} and Yee Chao and Wang, {Ling Wei} and Teng, {Hao Wei}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

doi = "10.1016/j.clcc.2023.03.003",

language = "English",

journal = "Clinical Colorectal Cancer",

issn = "1533-0028",

publisher = "Elsevier Inc.",

}

Chen, CW, Ou, TS, Chen, WS, Jiang, JK, Yang, SH, Wang, HS, Chang, SC, Lan, YT, Lin, CC, Lin, HH, Huang, SC, Cheng, HH, Yang, YW, Lin, YZ, Chao, Y, Wang, LW & Teng, HW 2023, 'Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability', Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2023.03.003

TY - JOUR

T1 - Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability

AU - Chen, Chih Wen

AU - Ou, Tao Shen

AU - Chen, Wei Shone

AU - Jiang, Jeng Kai

AU - Yang, Shung Haur

AU - Wang, Huann Sheng

AU - Chang, Shih Ching

AU - Lan, Yuan Tzu

AU - Lin, Chun Chi

AU - Lin, Hung Hsin

AU - Huang, Sheng Chieh

AU - Cheng, Hou Hsuan

AU - Yang, Yi Wen

AU - Lin, Yu Zu

AU - Chao, Yee

AU - Wang, Ling Wei

AU - Teng, Hao Wei

PY - 2023

Y1 - 2023

N2 - Background: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM. Methods: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal. Results: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis. Conclusions: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.

AB - Background: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM. Methods: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal. Results: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis. Conclusions: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.

KW - Anti-angiogenesis therapy

KW - Colorectal cancer

KW - Gene Ontology

KW - Overall Survival

UR - http://www.scopus.com/inward/record.url?scp=85153588463&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2023.03.003

DO - 10.1016/j.clcc.2023.03.003

M3 - Article

C2 - 37098452

AN - SCOPUS:85153588463

SN - 1533-0028

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

ER -

Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability

摘要

UN SDG

存取文件

其它文件與鏈接

指紋

引用此